Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

81.37 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
From Merck & Co., Inc.
Via Business Wire
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
What the Options Market Tells Us About Merck & Co
Via Benzinga
Exploring The Competitive Space: Merck &amp; Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Merck & Company Inc. (NYSE: MRK) Records 52-Week High Monday Morning
Via Investor Brand Network
2 Monster Stocks to Buy Without Any Hesitation
Investors can sleep easy at night with these stocks in their portfolios. 
Via The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks
Via Benzinga
Topics Economy
3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report
Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Drivers And Stock Pickers
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient. 
Via Talk Markets
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
Via Benzinga
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
Are these frigid Dow stocks in for a longer winter?
These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages. 
Via MarketBeat
Topics Economy Stocks
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... 
Via Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
3 companies that more than doubled analyst EPS estimates
Earning season is well underway, and the separation between the winners and losers continues to grow. Of the companies that have beat 
Via MarketBeat
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024." 
Via Benzinga
Merck Animal Health to Acquire Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued. 
Via Chartmill
7 Mutual Funds That Will Outperform in Any Market
While we’d all love to think we’re market geniuses, we could use the active management of outperforming mutual funds. 
Via InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.